Dementia - Pipeline Review, H1 2017

Published: Mar, 2017 | Pages: 219 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dementia - Pipeline Review, H1 2017, provides an overview of the Dementia (Central Nervous System) pipeline landscape.

Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation and cardiovascular diseases.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dementia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Dementia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dementia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 11, 17, 33, 12 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 12 and 4 molecules, respectively.

Dementia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Dementia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dementia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dementia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dementia (Central Nervous System)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dementia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dementia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 9
Global Markets Direct Report Coverage 9
Dementia - Overview 10
Dementia - Therapeutics Development 11
Pipeline Overview 11
Pipeline by Companies 12
Pipeline by Universities/Institutes 17
Products under Development by Companies 19
Products under Development by Universities/Institutes 24
Dementia - Therapeutics Assessment 25
Assessment by Target 25
Assessment by Mechanism of Action 29
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Dementia - Companies Involved in Therapeutics Development 36
Acorda Therapeutics Inc 36
Actinogen Medical Ltd 36
Adamas Pharmaceuticals Inc 37
AgeneBio Inc 37
Alector LLC 38
Allergan Plc 38
AlzProtect SAS 39
Amarantus Bioscience Holdings Inc 39
Anavex Life Sciences Corp 40
Asceneuron SA 40
Axon Neuroscience SE 41
Axovant Sciences Ltd. 41
BioArtic AB 42
Biogen Inc 42
Boehringer Ingelheim GmbH 43
Cortice Biosciences Inc 43
Daewoong Pharmaceutical Co Ltd 44
Echo Pharmaceuticals BV 44
Eisai Co Ltd 45
Eli Lilly and Company 45
H. Lundbeck A/S 46
Heptares Therapeutics Ltd 47
HSRx Group 47
Hyundai Pharmaceutical Co Ltd 48
Ildong Pharmaceutical Co Ltd 48
Immungenetics AG 49
ImStar Therapeutics Inc 49
Integrative Research Laboratories Sweden AB 50
Intellect Neurosciences Inc 50
INVENT Pharmaceuticals Inc 51
Ironwood Pharmaceuticals Inc 51
M3 Biotechnology Inc 52
MediPost Co Ltd 52
Neuraltus Pharmaceuticals Inc 53
Neurimmune Holding AG 53
Neuropore Therapies Inc 54
NsGene A/S 54
Oryzon Genomics SA 55
P2D Bioscience 55
Pacific Northwest Biotechnology LLC 56
Pharmasum Therapeutics AS 56
Prana Biotechnology Ltd 57
Sage Therapeutics Inc 57
Sinil Pharmaceutical Co Ltd 58
Stelic Institute & Co Inc 58
Stemedica Cell Technologies Inc 59
Sumitomo Dainippon Pharma Co Ltd 59
Suven Life Sciences Ltd 60
Sylentis SAU 60
TauRx Therapeutics Ltd 61
Voyager Therapeutics Inc 61
WhanIn Pharmaceutical Co Ltd 62
Zhejiang Hisun Pharmaceutical Co Ltd 62
Dementia - Drug Profiles 63
(donepezil hydrochloride + glycopyrrolate) - Drug Profile 63
(donepezil hydrochloride + memantine hydrochloride ER) - Drug Profile 64
(donepezil hydrochloride + solifenacin succinate) - Drug Profile 66
(glycopyrrolate + rivastigmine) - Drug Profile 68
AADvac-1 - Drug Profile 69
AD-35 - Drug Profile 71
ANAVEX-371 - Drug Profile 72
Antibody to Inhibit Tau Proteins for Corticobasal Degeneration - Drug Profile 74
Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile 75
ASN-561 - Drug Profile 76
AZP-2006 - Drug Profile 77
BAN-0805 - Drug Profile 79
BI-409306 - Drug Profile 80
CB-2233 - Drug Profile 82
CB-8411 - Drug Profile 83
Cell Therapy for Central Nervous System and Neurodegenerative Diseases - Drug Profile 84
choline alfoscerate SR - Drug Profile 85
CIDEM-162 - Drug Profile 86
D-217 - Drug Profile 87
dehydroevodiamine hydrochloride - Drug Profile 88
donepezil Depot - Drug Profile 89
donepezil Patch - Drug Profile 90
dronabinol - Drug Profile 91
Drugs for Dementia - Drug Profile 93
Drugs to Agonize Hepatocyte Growth Factor Receptor for Dementia - Drug Profile 94
Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment - Drug Profile 95
DWJ-1365 - Drug Profile 96
E-2027 - Drug Profile 97
E-2609 - Drug Profile 98
eltoprazine - Drug Profile 101
GIBH-130 - Drug Profile 106
Gln-1062 - Drug Profile 107
GTC-6000 - Drug Profile 110
gugulipid - Drug Profile 111
HOB-075 - Drug Profile 112
HTL-18318 - Drug Profile 113
intepirdine - Drug Profile 114
INV-331 - Drug Profile 117
IRL-752 - Drug Profile 118
IW-6463 - Drug Profile 119
landipirdine - Drug Profile 120
levetiracetam - Drug Profile 122
LUAF-20513 - Drug Profile 124
MM-201 - Drug Profile 125
Monoclonal Antibodies for Alzheimer's Disease and Vascular Dementia - Drug Profile 126
Monoclonal Antibodies to Inhibit SORT1 for Alzheimer's Disease and Dementia - Drug Profile 127
Monoclonal Antibodies to Inhibit Tau for CNS Disorders - Drug Profile 128
Monoclonal Antibody to Inhibit Tau for Central Nervous System Disorders - Drug Profile 129
monosodium luminol - Drug Profile 130
NAT - Drug Profile 132
nelotanserin - Drug Profile 133
Neurostem - Drug Profile 135
NI-205 - Drug Profile 137
NI-308 - Drug Profile 138
NNC-269100 - Drug Profile 139
NP-001 - Drug Profile 140
NPT100-18A - Drug Profile 143
NXN-413 - Drug Profile 144
NXN-613 - Drug Profile 145
ORY-2001 - Drug Profile 146
PAM-43 - Drug Profile 149
PBT-434 - Drug Profile 150
PD-2015 - Drug Profile 152
PD-2024 - Drug Profile 153
PD-2244 - Drug Profile 154
Peptide to Inhibit BACE for Cerebropathy and Dementia - Drug Profile 155
PST-900 - Drug Profile 156
rivastigmine - Drug Profile 157
salicylamine - Drug Profile 158
SGE-201 - Drug Profile 159
SIN-1502 - Drug Profile 160
Small Molecule for Vascular Dementia - Drug Profile 161
Small Molecule to Activate ABC Transporter for Neurodegeneration Disorders - Drug Profile 162
Small Molecule to Activate LPL for CNS and Metabolic Disorders - Drug Profile 163
Small Molecule to Agonize Dopamine D1 Receptor for Dementia Associated with Alzheimer's Disease - Drug Profile 164
Small Molecule to Inhibit Glycogene 5 for Dementia - Drug Profile 165
Small Molecule to Inhibit TNF-Alpha for CNS Disorders - Drug Profile 166
Small Molecules for Ophthalmology and CNS Disorders - Drug Profile 167
Small Molecules to Agonize HGFR for CNS Disorders - Drug Profile 168
Small Molecules to Agonize M1 Muscarinic Acetylcholine Receptor for Central Nervous System - Drug Profile 169
Small Molecules to Inhibit TANA for ALS, Alzheimer's Disease and Dementia - Drug Profile 170
SND-14 - Drug Profile 171
Stem Cell Therapy for Dementia Associated with Alzheimer's Disease - Drug Profile 172
SUVNI-1307014 - Drug Profile 174
SUVNI-1312004 - Drug Profile 175
Synthetic Peptides to Activate PACAP Receptor and Antagonize VPAC1, VPAC2 for Neurological Disorders - Drug Profile 176
TAK-070 - Drug Profile 177
TauC-3 - Drug Profile 178
tolfenamic acid - Drug Profile 180
TPI-287 - Drug Profile 181
TRx-0237 - Drug Profile 185
UE-2343 - Drug Profile 189
VYTAU-01 - Drug Profile 192
WIB-1001C - Drug Profile 193
zonisamide - Drug Profile 194
Dementia - Dormant Projects 196
Dementia - Discontinued Products 200
Dementia - Product Development Milestones 201
Featured News & Press Releases 201
Appendix 212
Methodology 212
Coverage 212
Secondary Research 212
Primary Research 212
Expert Panel Validation 212
Contact Us 212
Disclaimer 213

List of Tables

Number of Products under Development for Dementia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Dementia - Pipeline by Acorda Therapeutics Inc, H1 2017
Dementia - Pipeline by Actinogen Medical Ltd, H1 2017
Dementia - Pipeline by Adamas Pharmaceuticals Inc, H1 2017
Dementia - Pipeline by AgeneBio Inc, H1 2017
Dementia - Pipeline by Alector LLC, H1 2017
Dementia - Pipeline by Allergan Plc, H1 2017
Dementia - Pipeline by AlzProtect SAS, H1 2017
Dementia - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017
Dementia - Pipeline by Anavex Life Sciences Corp, H1 2017
Dementia - Pipeline by Asceneuron SA, H1 2017
Dementia - Pipeline by Axon Neuroscience SE, H1 2017
Dementia - Pipeline by Axovant Sciences Ltd., H1 2017
Dementia - Pipeline by BioArtic AB, H1 2017
Dementia - Pipeline by Biogen Inc, H1 2017
Dementia - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Dementia - Pipeline by Cortice Biosciences Inc, H1 2017
Dementia - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
Dementia - Pipeline by Echo Pharmaceuticals BV, H1 2017
Dementia - Pipeline by Eisai Co Ltd, H1 2017
Dementia - Pipeline by Eli Lilly and Company, H1 2017
Dementia - Pipeline by H. Lundbeck A/S, H1 2017
Dementia - Pipeline by Heptares Therapeutics Ltd, H1 2017
Dementia - Pipeline by HSRx Group, H1 2017
Dementia - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017
Dementia - Pipeline by Ildong Pharmaceutical Co Ltd, H1 2017
Dementia - Pipeline by Immungenetics AG, H1 2017
Dementia - Pipeline by ImStar Therapeutics Inc, H1 2017
Dementia - Pipeline by Integrative Research Laboratories Sweden AB, H1 2017
Dementia - Pipeline by Intellect Neurosciences Inc, H1 2017
Dementia - Pipeline by INVENT Pharmaceuticals Inc, H1 2017
Dementia - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017
Dementia - Pipeline by M3 Biotechnology Inc, H1 2017
Dementia - Pipeline by MediPost Co Ltd, H1 2017
Dementia - Pipeline by Neuraltus Pharmaceuticals Inc, H1 2017
Dementia - Pipeline by Neurimmune Holding AG, H1 2017
Dementia - Pipeline by Neuropore Therapies Inc, H1 2017
Dementia - Pipeline by NsGene A/S, H1 2017
Dementia - Pipeline by Oryzon Genomics SA, H1 2017
Dementia - Pipeline by P2D Bioscience, H1 2017
Dementia - Pipeline by Pacific Northwest Biotechnology LLC, H1 2017
Dementia - Pipeline by Pharmasum Therapeutics AS, H1 2017
Dementia - Pipeline by Prana Biotechnology Ltd, H1 2017
Dementia - Pipeline by Sage Therapeutics Inc, H1 2017
Dementia - Pipeline by Sinil Pharmaceutical Co Ltd, H1 2017
Dementia - Pipeline by Stelic Institute & Co Inc, H1 2017
Dementia - Pipeline by Stemedica Cell Technologies Inc, H1 2017
Dementia - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
Dementia - Pipeline by Suven Life Sciences Ltd, H1 2017
Dementia - Pipeline by Sylentis SAU, H1 2017
Dementia - Pipeline by TauRx Therapeutics Ltd, H1 2017
Dementia - Pipeline by Voyager Therapeutics Inc, H1 2017
Dementia - Pipeline by WhanIn Pharmaceutical Co Ltd, H1 2017
Dementia - Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H1 2017
Dementia - Dormant Projects, H1 2017
Dementia - Dormant Projects, H1 2017 (Contd..1), H1 2017
Dementia - Dormant Projects, H1 2017 (Contd..2), H1 2017
Dementia - Dormant Projects, H1 2017 (Contd..3), H1 2017
Dementia - Discontinued Products, H1 2017